MRC Technology, AstraZeneca Collaborate
News Jun 16, 2016
MRCT and AstraZeneca are now seeking academics with relevant epigenetics targets to collaborate with them to develop novel treatments for respiratory diseases, which affect millions of people every year.
Dr Justin Bryans, Director, Drug Discovery, at MRC Technology said: “By combining our expertise, we will generate more opportunities to translate early stage academic research into potential new therapies to benefit patients. We are aiming to accelerate the development of novel small molecule drugs that can specifically target epigenetic pathways involved in respiratory diseases.”
AstraZeneca and MRCT are particularly interested to hear from researchers studying epigenetic mechanisms involved in respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. In addition, they are also interested in epigenetic modulators acting in biological pathways relevant to respiratory, inflammatory or autoimmune disease, such as those involved in determining particular immune cell subsets or phenotypes (for example Tregs and T effector cells).
Drug discovery projects will be a multidisciplinary collaboration between academic scientists, AstraZeneca and MRCT. AstraZeneca and MRCT will provide proprietary small molecule collections, assay development and screening, medicinal chemistry, access to disease models for testing the molecules and project oversight.
Maarten Kraan, Head of the Respiratory, Inflammation and Autoimmune Innovative Medicines Unit at AstraZeneca, said: “Respiratory diseases are a key area of focus for AstraZeneca and one that represents a high unmet medical need. We are now starting to understand how epigenetic factors help to explain the generation of many chronic respiratory diseases such as asthma and COPD. These factors are also reversible, which makes them good targets for therapeutic intervention. This unique collaboration will allow us to work with a strong academic consortium and the best academic translational scientists across the world to advance medical science and accelerate the search for new treatments.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE